The aim of the study was to assess plasma concentration of catecholamines and asymmetric dimethyl arginine levels and a possible relationship to predict the mortality rates among hemodialysis patients. The study population comprised 27 subjects, aged 65-70 years. Each patient underwent dialysis thrice a week. Furthermore, the median duration of hemodialysis was 3.5 years. Based on the conducted research, it can be concluded that the concentrations of adrenaline and the level of asymmetric dimethylarginine have predictive value of mortality among hemodialysis patients. Of note, lowering plasma asymmetric dimethylarginine concentration may represent therapeutic target for prevention of progressive renal damage.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Agarwal R. et al.: Prevalence treatment and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med. 115 291 2003.
2. Aldamiz-Echevarria L. Andrade F.: Asymmetric dimethylarginine endothelial dysfunction and renal disease. Int. J. Mol. Sci.13 11288 2012.
3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res. 40 340 2012.
4. Arici M. Walls J.: End-stage renal disease atherosclerosis and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int. 59 407 2001.
5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med. 26 80 2013.
6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol. 159 217 2012.
7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302 1782 2009.
8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens. 15 901 1997.
9. Guerin A Pannier B London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.44 187 2007.
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Am. J. Kidney Dis. 39 1 2002.
11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc.Nephrol. 13 170 2002.
12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10 594 1999.
13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res. 27 143 2004.
14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant. 12 1187 1997.
15. Luyckx V.A. Brenner B.M. Low birth weight nephron number and kidney disease. Kidney Int. 97 68 2005.
16. Mallamaci F. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol. 15 435 2004.
17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int. 9 1 2013.
18. Perticone F. et al.: Endothelial dysfunction ADMA and insulin resistance in essential hypertension. Int. J. Cardiol. 142 236 2010.
19. Raptis V. Kapoulas S. Grekas D.: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton) 18 11 2013.
20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis 222 509 2012.
21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol. 20 945 2005.
22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul Gdańsk 2010.
23. Sarnak M.J. Levey A.S.: Epidemiology diagnosis and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis 10 169 2000.
24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res. 77 841 1995.
25. Sesti G. et al.: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Atherosclerosis 231 141 2013.
26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol.Rev. 6 82 2010.
27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy older adults of different ethnicities. Clin. Chem. 56 111 2010.
28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.Clin. J. Am. Soc. Nephrol. 6 1714 2011.
29. U.S. Renal Data System USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD 2013.
30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology 12 582 2007.
31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol. Genet. Metab. 91 309 2007.
32. Zoccali C. et al.: Asymmetric dimethylarginine C-reactive protein and carotid intima-media thickness in end-stage renal disease. J. Am.Soc. Nephrol. 13 490 2002.
33. Zoccali C. et al:. Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens. 18 1207 2000.